Skip to main content
Equibles
STRO logo

STRO · Sutro Biopharma, Inc.

Track STRO — free

Use STRO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about STRO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$21.04 -0.12 (-0.57%) At close · Aug 21
Market Cap
$348.87M
Shares
16.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$21.04 Open$21.39 Day$20.84–21.86 Since split$8.49–40.91 Avg vol 30d302K Short int1.7M · 10.5% float · 6.4d Short vol74% Last earningsAug 12, 2026 DataDec 2025–Aug 2026 Filing10-Q · Aug 12

Raw chart and full-history price indicators begin at the captured split on Dec 3, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on Dec 3, 2025.

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −20%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 39%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −8%
trailing
6-month return +2%
trailing
YTD return +82%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+24% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.52% of float · ▲ +5.6% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
97 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Fair
Revenue growth −26%
Y/Y
EPS growth +24%
Y/Y
Free cash flow $-178.8M
Balance sheet $54.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −50%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the 8-K filed Nov 6, 2025
Restructuring costs · fourth quarter of 2025 $4.1M – $4.3M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−20% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
39% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+24% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.52% of float · ▲ +5.6% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
97 holders — mid 3-yr range
Price context
position in its range since split · 2025-12-03
Range low $8 Now $21 · 39% Range high $41
vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $164.3M As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STRO
Sutro Biopharma, Inc.
this stock
$348.87M +81.8% -25.7% — 10.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
97
% held
99.5%
Net QoQ
+2.1M sh
Top holder
PERCEPTIVE ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
35
View
Short & Settlement
Short Interest Rising
Shares short
1.7M
Days to cover
6.4d
Change
+92.0K sh
View
Short Volume
Short vol %
74%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$25.0K
As of
Jul 23, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$102.5M
Net income (FY)
$-191.1M
EPS diluted
$-22.49
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
10
View
Proposed Sales
Value
$131.0K
Shares
8.9K
Filed
Jan 20, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

Raw-price comparisons begin at the captured split on Dec 3, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
STRO +2.7% -8.0% +2.4% -13.0% +81.9%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +4.1% -11.7% -9.2% -15.5% +69.6%
Key facts CIK 1382101 CUSIP 869367201 13F (30d) 96 filings 93 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)